Trial results

$CGON — cretostimogene

CG Oncology, Inc. (CGON) cretostimogene: trial results in intermediate-risk and high-grade Ta NMIBC, 2026.

Research by Catalyst Intel

The catalyst

"PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk and high-grade Ta NMIBC anticipated November 2026"

— CG Oncology, 8-K filed 2026-11-06 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

CGON-CRETOSTIMOGE-2026

Company

CG Oncology, Inc.

Kind

Trial results

Indication

intermediate-risk and high-grade Ta NMIBC

Window

2026-11-01 – 2026-11-30

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.